1. The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies
   Taylor Harding et al, 2019, Leukemia CrossRef
2. Treatment May Be Harmful: Mechanisms/Prediction/Prevention of Drug-Induced DNA Damage and Repair in Multiple Myeloma
   Claire Gourzones et al, 2019, Frontiers in Genetics CrossRef
3. Drug resistance in cancer: mechanisms and tackling strategies
   Tanweer Haider et al, 2020, Pharmacological Reports CrossRef
4. Concepts and Molecular Aspects in the Polypharmacology of PARP‐1 Inhibitors
   Daniela Passeri et al, 2016, ChemMedChem CrossRef
5. Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma
   Sara Ovejero et al, 2021, Exploration of Targeted Anti-tumor Therapy CrossRef
6. PARP Inhibitors and Haematological Malignancies—Friend or Foe?
   Kathryn A. Skelding et al, 2021, Cancers CrossRef
7. Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuriesin vitroandin vivo
   Feng Liu et al, 2016, PeerJ CrossRef
8. The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance
   Sara Ovejero et al, 2022, Frontiers in Immunology CrossRef
9. Expeditious synthesis of CF3-phenanthridones through a base-mediated cross-conjugated vinylogous benzannulation (VBA)
   Madhu Desagoni et al, 2025, Organic & Biomolecular Chemistry CrossRef
10. Coexisting Thalassemia, Immune Thrombocytopenic Purpura, and Multiple Myeloma With Osteopenia: Complex Hematologic Case in an Adult Asian Male Patient
    Javier B Chambi-Torres et al, 2024, Cureus CrossRef
11. PARP1 and POLD2 as prognostic biomarkers for multiple myeloma in autologous stem cell transplant
    Melissa Thomas et al, 2023, Haematologica CrossRef
12. Cross-conjugated vinylogous annulation of π-CF3-allyl Pd-complexes with 4-methyl-3-trifluoroacetyl-quinolones
    Chiliveru Priyanka et al, 2024, Chemical Communications CrossRef
13. Proteometabolomics of Melphalan Resistance in Multiple Myeloma
    David C. Koomen et al, 2019, Metabolomics CrossRef
14. PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias
    Claire Fritz et al, 2021, Blood Reviews CrossRef
15. Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma
    Sara Ovejero et al, 2021, Exploration of Targeted Anti-tumor Therapy CrossRef
16. Synthesis, Characterization, and In Vitro Studies of an Reactive Oxygen Species (ROS)-Responsive Methoxy Polyethylene Glycol-Thioketal-Melphalan Prodrug for Glioblastoma Treatment
    Natalia Oddone et al, 2020, Frontiers in Pharmacology CrossRef
17. The Modified Phenanthridine PJ34 Unveils an Exclusive Cell-Death Mechanism in Human Cancer Cells
    Malka Cohen-Armon, 2020, Cancers CrossRef
18. Stalled replication forks within heterochromatin require ATRX for protection
    M S Huh et al, 2016, Cell Death & Disease CrossRef
19. PARP inhibitor re‑sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis
    Jie Wu et al, 2018, Molecular Medicine Reports CrossRef
20. Targeting the DNA damage response in hematological malignancies
    Sanjay De Mel et al, 2024, Frontiers in Oncology CrossRef